Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TVRD Tvardi Therapeutics Inc

未开盘 06-02 16:00:00 EDT

3.17

-0.05

-1.55%

盘后3.17

+0.000.00%

17:44 EDT

最高3.25	最低3.11	成交量3.93万
今开3.13	昨收3.22	日振幅4.34%
总市值2,974万	流通市值2,466万	总股本938.13万
成交额12.48万	换手率0.51%	流通股本777.87万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":3.17,"timestamp":1780430400000,"preClose":3.22,"halted":0,"volume":39298,"hourTrading":{"tag":"盘后","latestPrice":3.17,"preClose":3.17,"latestTime":"17:44 EDT","volume":59,"amount":187.7267,"timestamp":1780436676876,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.015527950310559088,"floatShares":7778729,"shares":9381344,"eps":-2.482384,"marketStatus":"未开盘","change":-0.05,"latestTime":"06-02 16:00:00 EDT","open":3.13,"high":3.2497,"low":3.11,"amount":124808,"amplitude":0.043385,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.482384,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780473600000},"marketStatusCode":0,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":3.22,"preHourTrading":{"tag":"盘前","latestPrice":3.17,"preClose":3.22,"latestTime":"09:29 EDT","volume":1440,"amount":4725.060048,"timestamp":1780406968058,"change":-0.05,"changeRate":-0.015528,"amplitude":0.042981},"postHourTrading":{"tag":"盘后","latestPrice":3.17,"preClose":3.17,"latestTime":"17:44 EDT","volume":59,"amount":187.7267,"timestamp":1780436676876,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.593769,"impliedVol":0.5788,"impliedVolPercentile":0.1803},"requestUrl":"/m/hq/s/TVRD","defaultTab":"news","newsList":[{"id":"1165971805","title":"Tvardi Therapeutics Inc：现金储备预计足以支撑运营至临床数据公布期及2026年第四季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1165971805","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165971805?lang=zh_cn&edition=full","pubTime":"2026-05-08 19:10","pubTimestamp":1778238631,"startTime":"0","endTime":"0","summary":"生物制药公司Tvardi Therapeutics Inc近日宣布，其现有资金储备预计可充分支持公司运营至关键临床试验数据公布阶段，并持续维持至2026年第四季度。这一财务规划为公司在肿瘤治疗领域核心药物的临床开发提供了稳定保障。随着临床研究进入关键阶段，投资者可重点关注该公司在实体瘤和血液恶性肿瘤治疗领域的数据更新。稳定的现金储备为Tvardi Therapeutics在竞争激烈的生物科技赛道中提供了独特的续航优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178271385","title":"Tvardi Therapeutics Inc将于2026年6月公布Tti-109关键数据及临床开发战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1178271385","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178271385?lang=zh_cn&edition=full","pubTime":"2026-05-08 19:10","pubTimestamp":1778238625,"startTime":"0","endTime":"0","summary":"生物制药公司Tvardi Therapeutics Inc近日透露，其核心候选药物Tti-109的关键临床试验数据以及后续临床开发战略，预计将在2026年6月正式对外公布。\n此次即将披露的顶线数据备受业界关注，其结果将直接影响该药物未来的研发路径与商业化前景。公司计划基于这些数据制定明确的临床推进策略，为后续研究阶段提供清晰方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153510288","title":"Tvardi Therapeutics Inc 新一代STAT3抑制剂Tti-109一期临床健康受试者顶线数据预计2026年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1153510288","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153510288?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:13","pubTimestamp":1767878002,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc宣布，其新一代STAT3抑制剂Tti-109的一期临床试验取得重要进展。针对健康志愿者的顶线数据收集工作正按计划推进，预计将于2026年上半年完成。\n该研究旨在评估Tti-109的安全性、耐受性及药代动力学特征。STAT3作为关键信号传导蛋白，在多种肿瘤生长中扮演核心角色。Tti-109通过精准抑制STAT3活性，为晚期癌症治疗提供了新思路。\n目前临床试验进程符合预期时间表。若数据结果达到预设终点，将为后续针对实体瘤和血液恶性肿瘤的二期研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://tvarditherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.098},{"period":"1month","weight":0.0255},{"period":"3month","weight":-0.1827},{"period":"6month","weight":-0.2184},{"period":"1year","weight":-0.8864},{"period":"ytd","weight":-0.2512}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.287},{"period":"ytd","weight":0.1124}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tvardi Therapeutics, Inc.于2017年12月20日注册成立，是一家总部位于德克萨斯州休斯顿的特拉华州公司。该公司是一家临床阶段的生物制药公司，专注于开发针对STAT3的新型口服小分子疗法，以治疗具有重大未满足需求的纤维化驱动疾病。基于其创始人的开创性工作和对转录因子STAT3的深刻理解，该公司设计了一种创新方法来直接抑制STAT3，这是一种经过高度验证但在历史上是不可药物的靶点。利用这些专业知识，该公司正在开发具有差异化作用机制和方便的口服给药的STAT3抑制剂管道。该公司的主要候选产品TTI-101目前处于2期临床开发阶段，用于治疗纤维化驱动的疾病，初步重点是特发性肺纤维化、IPF和肝细胞癌、HCC。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.032141},{"month":2,"riseRate":0.384615,"avgChangeRate":0.018638},{"month":3,"riseRate":0.538462,"avgChangeRate":0.004527},{"month":4,"riseRate":0.230769,"avgChangeRate":-0.045527},{"month":5,"riseRate":0.615385,"avgChangeRate":0.014602},{"month":6,"riseRate":0.538462,"avgChangeRate":-0.019734},{"month":7,"riseRate":0.5,"avgChangeRate":0.091173},{"month":8,"riseRate":0.5,"avgChangeRate":0.010865},{"month":9,"riseRate":0.25,"avgChangeRate":-0.036951},{"month":10,"riseRate":0.5,"avgChangeRate":-0.10272},{"month":11,"riseRate":0.5,"avgChangeRate":0.037928},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016361}],"exchange":"NASDAQ","name":"Tvardi Therapeutics Inc","nameEN":"Tvardi Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tvardi Therapeutics Inc(TVRD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tvardi Therapeutics Inc,TVRD,Tvardi Therapeutics Inc股票,Tvardi Therapeutics Inc股票老虎,Tvardi Therapeutics Inc股票老虎国际,Tvardi Therapeutics Inc行情,Tvardi Therapeutics Inc股票行情,Tvardi Therapeutics Inc股价,Tvardi Therapeutics Inc股市,Tvardi Therapeutics Inc股票价格,Tvardi Therapeutics Inc股票交易,Tvardi Therapeutics Inc股票购买,Tvardi Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tvardi Therapeutics Inc(TVRD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}